Publications
- Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed/refractory chronic lymphocytic leukaemia: A real-world analysis from the Chronic Lymphocytic Leukemia Patients Registry (CLLEAR)2023 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové, Third Faculty of Medicine
- COVID-19 in patients with chronic lymphocytic leukemia: a multicenter analysis by the Czech CLL study group2023 | Faculty of Medicine in Pilsen, Faculty of Medicine in Hradec Králové, Central Library of Charles University
- A comprehensive assessment of lymphocyte subsets, their prognostic significance, and changes after first-line therapy administration in patients with chronic lymphocytic leukemia2023 | Faculty of Medicine in Hradec Králové
- Severe secondary immune thrombocytopenia in a patient with chronic lymphocytic leukemia2022 | Faculty of Medicine in Hradec Králové, Faculty of Pharmacy in Hradec Králové
- Chylothorax treatment with thoracic duct embolization2022 | Faculty of Medicine in Hradec Králové
- External validation of International Prognostic Score for asymptomatic early stage chronic lymphocytic leukaemia and proposal of an alternative score2021 | Faculty of Medicine in Hradec Králové, Third Faculty of Medicine
- Rituximab, Cyclophosphamide and Dexamethasone (RCD) Chemoimmunotherapy for Relapsed Chronic Lymphocytic Leukaemia2021 | Faculty of Medicine in Hradec Králové, Third Faculty of Medicine
- Chemoimmunotherapy in the First-Line Treatment of Chronic Lymphocytic Leukaemia: Dead Yet, or Alive and Kicking?2021 | Faculty of Medicine in Hradec Králové
- Changes in the immune system in untreated patients with chronic lymphocytic leukaemia - part 2: innate immune system +12021 | Faculty of Medicine in Hradec Králové
- Changes in the immune system of untreated patients with chronic lymphocytic leukaemia - Part 1: Adaptive immunity2021 | Faculty of Medicine in Hradec Králové
Loading network view...